Antifungal Drug Mechanisms and Applications

Antifungal chemotherapy relies on exploiting fundamental differences between fungal pathogens and their human hosts. The principal drug classes include azoles, which inhibit the cytochrome P450 enzyme lanosterol 14-α-demethylase to deplete ergosterol and disrupt membrane structure; polyenes, which bind ergosterol directly to create transmembrane pores; echinocandins, which block β-(1,3)-d-glucan synthase and compromise cell-wall integrity; and fluoropyrimidines, which interfere with nucleic acid synthesis. Clinical use spans topical and systemic formulations to treat superficial dermatophytoses, invasive candidiasis, aspergillosis and cryptococcosis, as well as agricultural applications to protect crops from phytopathogenic fungi. Despite advances, host toxicity and the emergence of resistance and tolerance phenomena remain pressing challenges. Resistance mechanisms include target overexpression, point mutations, efflux-pump upregulation and biofilm formation. To counteract these, researchers are exploring combination therapies, novel drug carriers such as nanoparticles, structure-guided modification of established scaffolds and immunotherapeutic strategies, including vaccines and adjuvant compounds. Progress in high-throughput screening and structure-function studies has identified antivirulence agents that inhibit biofilm formation or filamentation, offering the prospect of reduced selective pressure for resistance. Overall, the field is shifting towards integrated approaches that combine conventional fungicides with targeted adjuvants to enhance efficacy, minimise toxicity and forestall the evolution of drug-tolerant and drug-resistant fungal populations.

Research from Nature Portfolio

Recent studies have revealed that triazole fungicides activate both apoptosis and macroautophagy in crop pathogens by inducing reactive oxygen species, uncovering programmed cell-death pathways as critical determinants of fungicidal activity. This insight extends beyond membrane perturbation to implicate intracellular signalling cascades in azole lethality and suggests that dual inhibition of these pathways may mitigate resistance development. In parallel, investigations into Candida albicans have distinguished antifungal tolerance from classical resistance. Subpopulations of tolerant cells can grow slowly at fluconazole concentrations above the minimal inhibitory concentration, linked to reduced intracellular drug accumulation. Adjuvant agents that suppress tolerance without altering resistance have demonstrated enhanced clearance in infection models, highlighting tolerance quantification as a valuable predictor of clinical outcome and a novel therapeutic target.

Antifungal Drug Mechanisms and Applications publication trend

The graph below shows the total number of articles in antifungal drug mechanisms and applications across all publications each year (not limited to Nature Index journals).

Technical terms

Ergosterol: A sterol component of fungal cell membranes essential for membrane fluidity and integrity.

Lanosterol 14-α-demethylase: A cytochrome P450 enzyme targeted by azole antifungals to block ergosterol biosynthesis.

β-(1,3)-d-Glucan synthase: A membrane-associated enzyme synthesising a key polysaccharide in the fungal cell wall.

Antifungal tolerance: The ability of a fungal subpopulation to survive and grow slowly at drug concentrations above the minimal inhibitory concentration.

Efflux pump: A transmembrane protein that expels antifungal agents from the cell, contributing to resistance.

References

1. Azoles activate type I and type II programmed cell death pathways in crop pathogenic fungi. Nature Communications (2024).
2. Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia. Nature Communications (2018).
3. Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium. Antibiotics (2020).
4. A novel small molecule inhibitor of Candida albicans biofilm formation, filamentation and virulence with low potential for the development of resistance. npj Biofilms and Microbiomes (2015).
5. Antifungal Drugs. Metabolites (2020).
6. New Horizons in Antifungal Therapy. Journal of Fungi (2016).